Insights On Upstream Manufacturing

31. Develop Clones In Just 9 Weeks From Transfection With Up To 4X Titer 6/15/2026

    Transposon-based cell line development cuts timelines by 10 weeks and hits titers of 4.8 g/L in 17 days. See how SynWeave delivers measurable biologics manufacturing gains.

32. Direct Scale Up From Clone To 2K GMP Batches 6/15/2026

    N-1 perfusion technology increased antibody titers 1.5–4.5x over conventional fed-batch methods. See how high seed density and media blending cut costs and maximize suite utilization.

33. Leveraging Integrated Media Services For Speed And Efficiency 6/12/2026

    Uncertainty in media stability can limit efficiency and scalability in biologics manufacturing. See how a data-driven approach enables more predictable planning and reduces operational strain.

34. Enabling Clinical-Grade Automated Manufacturing Of γδ T Cells 6/12/2026

    Explore smarter approaches to γδ T cell manufacturing, including scalable expansion, efficient transduction, and streamlined analytics, as well as how to build workflows that support validation.

35. Establishing The First Chinese Haplobank Of Clinical-Grade hiPSCs 6/11/2026

    Learn how automated, closed workflows and GMP-ready infrastructure are advancing pluripotent stem cell development from scalable expansion and differentiation to building regional capacity.

36. Achieving Clinical Quality For Human iPSC Generation And Expansion 6/11/2026

    Gain practical insight into building scalable stem cell manufacturing processes while maintaining consistency and quality across workflows, as well as in-depth guidance to support your strategy.

37. Automated GMP-Compliant PSC Banking In A Closed System 6/11/2026

    Explore advances in automated adherent cell culture and the optimization of large-scale iPSC expansion, as well as how standardization and process control are improving reproducibility.

38. Manufacturing GMP-Compliant iPSCs In Closed And Open Systems 6/11/2026

    Gain practical insight into scaling human iPSC manufacturing with expert perspectives on process control, reproducibility, and automated workflows designed to support stem cell expansion.

39. Advancing Clinical-Grade TIL Therapy Manufacturing 6/11/2026

    TIL therapy continues to advance, but manufacturing complexity limits its potential. See how automated workflows for generating tumor-reactive T cells can improve consistency, scalability, and readiness.

40. Automated And Streamlined Manufacturing Of TIL Therapies 6/11/2026

    Advances in TIL therapy are driving a shift from manual processes to streamlined, automated manufacturing. Discover how improved workflows and early clinical results are shaping cancer treatments.